Table 2.
Descriptive data for younger and older participants, pre-vaccine
| CoronAVI@S | KING Cohort extension | P-value | |
|---|---|---|---|
| Infected | Infected | ||
| N = 82 | n = 64 | ||
| Age, years, median [IQR] | 87 [81–90] | 44 [38–51] | <0.001 |
| Age, years, n (%) | |||
| <45 | 0 (0) | 36 (56) | |
| 45–65 | 0 (0) | 27 (42) | |
| 65–85 | 37 (45) | 0 (0) | |
| >85 | 45 (55) | 0 (0) | |
| Female, n (%) | 66 (80) | 47 (73) | 0.33 |
| AGM levela,b, n (%) | |||
| 1 | 0 (0) | 32 (50) | <0.001 |
| 2 | 4 (5) | 17 (27) | <0.001 |
| 3 | 38 (46) | 11 (17) | <0.001 |
| 4 | 41 (49) | 0 (0) | <0.001 |
| History of SARS-CoV-2 infection, n (%) | 82 (100) | 64 (100) | 1 |
| Pre-vaccine visit | |||
| Time from PCR positive/symptoms to sample extraction, months, median [IQR] | 6.5 [6.0–6.9] | 6.6 [6.1–7.4] | 0.04 |
| Detection of SARS-CoV-2-specific antibodies, n (%) | 81 (99) | 52 (81) | 0.0002 |
| Medical assistance, n (%) | 5 (6) | 0 (0) | 0.25 |
aAGM: Stratum of Adjusted Morbidity ranging from 1 to 4 according to the number of comorbidities and their need for health care. AGM level was not available for four individuals from the KING Cohort extension bAGM level was not available for four individuals from the KING Cohort extension. Significant p-values are indicated in bold.